Cosmos Health Expands Order Book with Contract Manufacturing Agreement with Medical Pharmaquality S.A. for 3 Million MYCOFAGYL® Pessaries Annually

Core Insights - Cosmos Health Inc. has signed a contract manufacturing agreement with Medical Pharmaquality S.A. for the production of MYCOFAGYL® pessaries, expanding its pharmaceutical product pipeline [1][2] - MYCOFAGYL® combines Metronidazole (500mg) and Nystatin (100,000 IU) to treat vaginal infections, with an anticipated production of 3 million pessaries annually [2][3] - The agreement enhances Cana Laboratories' portfolio in gynecology and reinforces its reputation as a reliable partner in the pharmaceutical industry [4][5] Company Overview - Cosmos Health Inc. is a diversified global healthcare group that owns various pharmaceutical and nutraceutical brands and operates through its subsidiary, Cana Laboratories S.A., which is certified under European Good Manufacturing Practices [7] - The company is involved in the manufacturing and distribution of pharmaceuticals, food supplements, and medical devices, and is expanding its operations across Europe, Asia, and North America [7] - Cosmos Health has established R&D partnerships targeting major health disorders and has entered the telehealth space through the acquisition of ZipDoctor, Inc. [7]